Navigation Links
GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloitte's 2010 Technology Fast 500™
Date:10/25/2010

ORLANDO, Fla., Oct. 25 /PRNewswire/ -- GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, today announced that it ranked number 62 on Technology Fast 500, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.  Rankings are based on percentage of fiscal year growth during the period from 2005-2009.  GeneLink grew 2057 percent during this period. GeneLink ranked 17th overall in the Biotechnology/Pharmaceutical sector.

GeneLink's CEO Gary Beeman credits the Company's genetic science and its DNA-guided personalized health products for the dramatic revenue growth.  "GeneLink's growth is a testament to the pioneering research by our scientists over the past decade as well as an indicator of the growing interest in personalized wellness products customized to each individual's DNA."

"GeneLink and the other 2010 Technology Fast 500™ winners forged ahead in a challenging economic environment to realize exceptional growth," said Phil Asmundson, vice chairman and Deloitte's U.S. technology, media and telecommunications leader.  "Deloitte commends GeneLink for this impressive accomplishment."

"GeneLink has proven itself to be one of the fastest growing tech companies in North America, and we are proud to honor them as one of the 2010 Technology Fast 500," said Mark Jensen, managing partner, Venture Capital Services, Deloitte & Touch LLP.

GeneLink previously ranked 92nd in the  Deloitte "Fast 500" in 2008.


About GeneLink:

GeneLink is a wellness company engaged in genetic test and product development.  GeneLink's patented technologies include proprietary genetic assessments and products for personalized health, beauty and wellness.  For information, visit www.genelinkbio.com.

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

As used in this document, "Deloitte" means Deloitte LLP.  Please see www.deloitte.com/us/about  for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.



'/>"/>
SOURCE GeneLink BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeneLink Announces HelixLife Private Label Distribution Agreement
2. GeneLink Reports First Quarter Gains
3. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
4. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
5. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
8. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
9. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
10. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
11. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 05, 2016 , ... This composition patent, U.S. Patent No. ... The composition claims are not limited to any particular process to make or ... carbon fibers, graphene, and other materials. A continuation application, U.S. Patent App. ...
(Date:12/5/2016)... , Dec. 5, 2016  Renova™ Therapeutics, ... congestive heart failure and other chronic diseases, announced ... the company as Chief Financial Officer (CFO), effective ... with 20 years of experience in financial management ... biotech and software companies. Most recently, Ms. Bovenizer ...
(Date:12/5/2016)... , December 5, 2016 The ... with almost $108 billion of revenue and some $890 ... were spent on global biopharmaceuticals, and this figure is ... Stock-Callers.com has lined up these four equities for assessment: ... Pharmaceuticals Inc. (NASDAQ: ACAD ), Acorda Therapeutics ...
(Date:12/2/2016)... ... ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility in ... Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski will meet ... to discuss the benefits of a viscoelastic disc. AxioMed received CE mark in ...
Breaking Biology Technology:
(Date:11/30/2016)... SAN FRANCISCO and WARSAW, Poland , Nov. 30, 2016 ... sleeping. It is one of the most crucial aspects of recovery so we need ... host of serious health risks, including heart problems, high blood pressure, stroke, diabetes, and ... family and friends sleep and find a Christmas present that could help them to ... ...
(Date:11/29/2016)... Lithuania , Nov. 29, 2016 /PRNewswire/ ... biometric identification and object recognition technologies, today ... (SDK) for fingerprint recognition solutions that run ... a fingerprint template using less than 128KB ... in compact devices that have limited on-board ...
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
Breaking Biology News(10 mins):